Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Patorno, E. [1 ]
Pawar, A. [1 ]
Franklin, J. M. [1 ]
Najafzadeh, M. [1 ]
Deruaz-Luyet, A. [2 ]
Brodovicz, K. G. [3 ]
Sambevski, S. [4 ]
Bessette, L. G. [1 ]
Kulldorff, M. [1 ]
Schneeweiss, S. [1 ]
机构：
[1] Harvard Med Sch, Div Pharmacoepidemiol, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Int GmbH, Corp Dept Med, Ingelheim, Germany
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷
关键词：
Sodium glucose co-transport inhibitor 2; Healthcare utilization; Diabetic ketoacidosis;
D O I：
10.1016/j.metabol.2019.12.072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Empagliflozin and the risk of heart failure hospitalisation in routine clinical care: An interim analysis from the EMPagliflozin compaRative EffectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Bartels, D. B.
    Gopalakrishnan, C.
    Kulldorff, M.
    Schneeweiss, S.
    DIABETIC MEDICINE, 2019, 36 : 47 - 47
  • [22] Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study
    Tesfaye, Helen
    Wang, Katherine M.
    Zabotka, Luke E.
    Wexler, Deborah J.
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo
    Paik, Julie M.
    Patorno, Elisabetta
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (10) : 1870 - 1879
  • [23] Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Pawar, A.
    Patorno, E.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Ustyugova, A.
    Gautam, N.
    Ortiz, A. Santiago
    Schneeweiss, S.
    Najafzadeh, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3063 - 3063
  • [24] Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Karasik, Avraham
    Lanzinger, Stefanie
    Tan, Elise Chia -Hui
    Yabe, Daisuke
    Kim, Dae Jung
    Sheu, Wayne H. -H
    Melzer-Cohen, Cheli
    Holl, Reinhard W.
    Ha, Kyoung Hwa
    Khunti, Kamlesh
    Zaccardi, Francesco
    Subramanian, Anuradhaa
    Nirantharakumar, Krishnarajah
    Nystrom, Thomas
    Niskanen, Leo
    Jensen, Majken Linnemann
    Hoti, Fabian
    Klements, Riho
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Koeneman, Lisette
    Vistisen, Dorte
    Carstensen, Bendix
    Halvorsen, Sigrun
    Langslet, Gisle
    Farsani, Soulmaz Fazeli
    Patorno, Elisabetta
    Nunez, Julio
    DIABETES & METABOLISM, 2023, 49 (02)
  • [25] Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
    Seino, Yutaka
    Kim, Dae Jung
    Yabe, Daisuke
    Tan, Elise Chia-Hui
    Chung, Wook-Jin
    Ha, Kyoung Hwa
    Nangaku, Masaomi
    Node, Koichi
    Klement, Riho
    Yasui, Atsutaka
    Lei, Wei-Yu
    Lee, Sunwoo
    Kyaw, Moe H.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Sheu, Wayne H-H
    ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (01)
  • [26] Reduced healthcare utilization in patients using Empagliflozin: An interim analysis from the Empagliflozin comparative effectiveness and safety (EMPRISE) study
    Najafzadeh, Mehdi
    Pawar, Ajinkya
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Ustyugova, Anastasia
    Bessette, Lily G.
    Gautam, Nileesa
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 223 - 224
  • [27] REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Najafzadeh, M.
    Pawar, A.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Ustyugova, A.
    Bessette, L. G.
    Gautam, N.
    Schneeweiss, S.
    Patorno, E.
    VALUE IN HEALTH, 2019, 22 : S161 - S161
  • [28] Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo
    Tesfaye, Helen
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Jawaid, Dureshahwar
    Wexler, Deborah J.
    Glynn, Robert
    Koeneman, Lisette
    Luyet, Anouk Deruaz
    Paik, Julie
    Patorno, Elisabetta
    CIRCULATION, 2021, 144
  • [29] Cardiovascular effectiveness of empagliflozin compared to DPP4 inhibitors and to GLP1 receptor agonists: Interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 119 - 119
  • [30] Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
    Vistisen, Dorte
    Carstensen, Bendix
    Elisabetta, Patorno
    Lanzinger, Stefanie
    Tan, Elise Chia-Hui
    Yabe, Daisuke
    Kim, Dae Jung
    Sheu, Wayne H. -H.
    Melzer-Cohen, Cheli
    Holl, Reinhard W.
    Nunez, Julio
    Ha, Kyoung Hwa
    Halvorsen, Sigrun
    Langslet, Gisle
    Karasik, Avraham
    Nystrom, Thomas
    Niskanen, Leo
    Guleria, Sonia
    Klement, Riho
    Carrasco, Marc
    Foersch, Johannes
    Shay, Christina
    Koeneman, Lisette
    Hoti, Fabian
    Farsani, Soulmaz Fazeli
    Khunti, Kamlesh
    Zaccardi, Francesco
    Subramanian, Anuradhaa
    Nirantharakumar, Krishnarajah
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
12345